Product Name: FRAP1 (2475-2484) pS2478+pS2481
Product Number: PE-04AMM95
Size: 200 µg      Price:71.00
1 mg      $US142.00
5 mg      311.00
Peptide Name: FRAP1 (2475-2484) pS2478+pS2481

Product Use: Services as a blocking peptide for use with the mTOR-pS2478+pS2481 rabbit polyclonal antibody (Cat. No.: AB-PK730) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the C-terminal fifth of the kinase at the end of the PI3_PI4-kinase domain. S2478 and S2481 phosphorylation stimulate phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: VPE-pS-IH-pS-FIG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1419.39 Da

Peptide Purity Percent after Synthesis and Purification: 95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: FRAP1 - pS2478+pS2481 phosphosite-specific antibody (Cat. No.: AB-PK730)

Scientific Background: mTOR (FRAP1) is a protein-serine/threonine kinase of the Atypical group and PIKK family. It mediates cell growth, metabolism, and survival. It regulates various cellular pathways such as insulin signalling, eIF4e and p70S6 kinase activation for protein synthesis, HIFa, VEGF, nutrient and hormone signals, ribosome biogenesis, regulation of cell cycle progression, angiogenesis, cell polarity and cytokeleton reorganization. Phosphorylation of S2448 and S2481 increases its phosphotransferase activity, and it is stimulated by RHEBm. Phosphorylation of T2446 inhibits phosphorylation of the S2448 activatory site. It is also negatively regulated by DEPDC6. Dysregulation in signalling that leads to constant activation of mTOR lead to uncontrolled proliferation and cell cycle progression and oncogensis. Increased invasiveness has also be shown do be associated with mTOR activity. While it features a wide range of mutations, this might reflect the very large size of the protein rather than its identification as a tumour suppressor protein. Cancer-related mutations for mTOR in human tumours point to a gain of function of the protein kinase, indicating that it might function as an oncoprotein (OP). The active form of the protein kinase normally acts to promote tumour cell proliferation. mTOR has been linked with Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma (SEGA), Lymphangioleiomyomatosis (LAM), Tuberous Sclerosis Complex, Plasmablastic Lymphoma (PBL), Ewing's tumours, and Kidney Angiomyolipoma.